Gilead Sciences ( NASDAQ: GILD) was upgraded to Buy from Hold at Truist after the company raised full year sales and profit outlook, and reported upbeat Q2 earnings. The California based biotech raised its full year adjusted profit to a range between $7.95 per share and $8.25 per share, as demand for its HIV products showed robust growth.

Fintel reports that on August 8, 2025, Truist Securities upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold to Buy. Analyst Price Forecast Suggests 9.43% Upside As of August 5, 2025,